Shape Therapeutics and VectorY Therapeutics announced a collaboration giving VectorY exclusive options to evaluate Shape's deep brain-penetrating AAV capsid technology, SHP-DB1, against multiple neurodegenerative disease targets. The deal could reach $1.2 billion in upfront and milestones. Concurrently, Biogen acquired Alcyone Therapeutics for $85 million, accessing an implantable device to improve delivery of RNA therapeutics into the spinal canal. These partnerships underscore a growing focus on advanced viral vector platforms and delivery technologies for neurological conditions.